Expanded Japanese approval clears way to earlier stage Humira use
This article was originally published in Scrip
Executive Summary
Abbott/Eisai's tumour necrosis factor-alpha inhibitor Humira (adalimumab) has been approved in Japan for the additional indication of inhibition of structural damage in the joints of patients with rheumatoid arthritis (RA).